Boston Scientific
BSX
$44.96
-0.04%
Boston Scientific Corp. is a global medical device company specializing in less invasive technologies across cardiovascular, endoscopy, urology, and neuromodulation, with products ranging from coronary stents to implantable defibrillators. As a top-tier player in the medical devices industry, it competes with the likes of Medtronic and Abbott, leveraging a broad portfolio and a strong pipeline of innovative therapies. The current investor narrative is dominated by a steep share price decline of over 55% in the past year, driven by disappointing clinical trial results and broader market sell-offs, yet the company continues to make strategic moves such as a $1.5 billion investment in MiRus to enter the high-growth TAVR market, signaling confidence in long-term growth. Wall Street remains largely bullish, with a consensus 'buy' rating, but the stock's sharp correction has raised questions about near-term execution and valuation support.…
BSX
Boston Scientific
$44.96
Related headlines
Investment Opinion: Should I buy BSX Today?
Based on the analysis, I rate Boston Scientific as a Buy, with a thesis that the market has overreacted to clinical setbacks, creating an attractive entry point for long-term investors. The consensus rating is 'buy' with an average target price of $62.69, implying a 31.2% upside from the current price. The company's robust revenue growth, high margins, and strategic expansion into TAVR support this view.
Sign up to view all
BSX 12-Month Price Forecast
The AI model assesses Boston Scientific as a bullish opportunity over the next 12 months, driven by solid revenue growth, a reasonable forward valuation, and positive analyst sentiment. The key risk is the potential for further clinical disappointments, which could undermine the bull case. If the company delivers on its growth promises and successfully enters the TAVR market, the stock could see significant upside. However, if execution falters, the stock could remain range-bound or decline further. The model would upgrade its stance if revenue growth accelerates above 15% or if major pipeline milestones are achieved, and downgrade if clinical failures persist or revenue growth decelerates below 8%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $62.69 and implied upside of +39.4% versus the current price.
Average Target
$62.69
0 analysts
Implied Upside
+39.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $94
Analyst target range
The target price range spans from a low of $44.00 to a high of $94.00, with the high target suggesting a potential doubling from current levels, likely predicated on successful TAVR market entry and a recovery in growth rates. The low target, near the current price, reflects downside risks from ongoing clinical and regulatory challenges. The wide spread between the low and high targets indicates significant uncertainty about the company's future performance, but the overall bullish tilt and recent reaffirmations suggest that analysts view the sell-off as overdone, presenting a potential buying opportunity for long-term investors.
Drowning in data?
Find the real signal!
Bulls vs Bears: BSX Investment Factors
Boston Scientific presents a mixed picture: strong operational performance with double-digit revenue growth and high margins contrasts sharply with a severe stock price decline driven by clinical disappointments and market skepticism. The bull case is supported by solid fundamentals, strategic expansion into TAVR, and an attractive forward valuation, while the bear case highlights the risk of over-optimistic earnings expectations and continued negative momentum. Currently, the evidence slightly favors the bull side, as the market may have overreacted to setbacks, but the key tension lies in whether the company can execute on its pipeline and deliver the earnings growth implied by the forward PE. If clinical outcomes improve and revenue growth sustains, the stock could recover significantly; otherwise, further downside is possible.
Bullish
- Robust Revenue Growth: Q1 2026 revenue grew 11.58% YoY to $5.203B, with sequential acceleration from $4.663B in Q1 2025. This consistent growth across quarters indicates strong underlying demand for Boston Scientific's diversified product portfolio.
- Strategic TAVR Market Entry: The $1.5B investment in MiRus provides a low-risk entry into the high-growth TAVR market, a significant expansion opportunity. This move is supported by Wall Street, with analysts viewing it as a catalyst for future growth.
- Strong Profitability Metrics: Gross margin stands at 69.0% and operating margin at 19.8%, reflecting efficient operations. Net margin of 14.4% demonstrates the company's ability to convert revenue into profit, supporting its investment case.
- Attractive Forward Valuation: With a forward PE of 13.92x, the stock trades at a significant discount to its trailing PE of 48.65x, implying the market expects substantial earnings growth. This suggests potential upside if the company meets earnings expectations.
Bearish
- Severe Share Price Decline: The stock has fallen 55.45% over the past year, from a 52-week high of $109.50 to $47.80. This dramatic decline reflects significant negative sentiment and has eroded investor confidence.
- Disappointing Clinical Trial Results: Recent clinical trial results have been underwhelming, leading to a sharp sell-off in March 2026. This raises concerns about the company's pipeline and future product approvals, which are critical for growth.
- High Trailing Valuation: The trailing PE of 48.65x is elevated, suggesting that the market had priced in high growth expectations that have not materialized. This leaves the stock vulnerable to further de-rating if earnings disappoint.
- Negative Relative Strength: The stock's relative strength over the past year is -74.1%, significantly underperforming the S&P 500. This indicates persistent selling pressure and a lack of investor interest, which could continue.
BSX Technical Analysis
Boston Scientific's stock is in a pronounced downtrend, with a 1-year price change of -55.45%, and the current price of $47.80 sits near the lower end of its 52-week range, at approximately 8.5% above the low of $42.20 and 56.3% below the high of $109.50. This positioning near the lows suggests a market that has priced in significant negative sentiment, but also potential value if fundamentals stabilize. The stock's beta of 0.568 indicates it is less volatile than the broader market, yet the magnitude of the decline underscores company-specific headwinds rather than systemic risk.
Beta
0.57
0.57x market volatility
Max Drawdown
-60.6%
Largest decline past year
52-Week Range
$42-$108
Price range past year
Annual Return
-58.4%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | -10.9% | -1.4% |
| 3m | -4.7% | +3.3% |
| 6m | -35.0% | +15.1% |
| 1y | -58.4% | +17.2% |
| ytd | -52.5% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Revenue growth remains robust, with the most recent quarter (Q1 2026) showing revenue of $5.203 billion, an 11.58% year-over-year increase, and sequential growth from $4.663 billion in Q1 2025. Over the past year, quarterly revenue has consistently risen from $4.561 billion in Q4 2024 to $5.286 billion in Q4 2025, indicating a steady acceleration. The cardiovascular segment, which generated $3.493 billion in the latest quarter, is the primary growth driver, while MedSurg contributed $1.814 billion, reflecting a diversified portfolio. This growth trajectory supports the company's investment case, though the market's focus on clinical setbacks has overshadowed the operational momentum.
Quarterly Revenue
$5.2B
2026-03
Revenue YoY Growth
+11.6%
YoY Comparison
Gross Margin
69.4%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Given that Boston Scientific is profitable, the price-to-earnings (PE) ratio is the primary valuation metric. The trailing PE stands at 48.65x, while the forward PE is significantly lower at 13.92x, implying that the market expects substantial earnings growth, likely driven by recent acquisitions and pipeline advancements. This wide gap between trailing and forward multiples suggests that the market is pricing in a near-term earnings surge, which may be overly optimistic given the recent clinical disappointments.
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~88x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. The company's debt-to-equity ratio of 0.51 indicates moderate leverage, but with a current ratio of 1.62, liquidity appears adequate. However, the high trailing PE of 48.65x suggests that the stock is priced for perfection, leaving little room for error. If revenue growth decelerates or margins compress, the stock could face a significant de-rating. Additionally, the company's reliance on continued growth to justify its valuation is a risk, as any slowdown could trigger a sharp correction. The recent clinical trial disappointments highlight the inherent risks in the medical device industry, where pipeline failures can severely impact investor sentiment.
FAQ
The key risks include: 1) clinical trial failures that could damage pipeline credibility and future growth prospects, as evidenced by recent disappointments; 2) high valuation on trailing earnings, leaving the stock vulnerable to de-rating if growth slows; 3) competitive pressures from larger players like Medtronic and Abbott, which could limit market share gains; and 4) macro risks, such as healthcare policy changes or economic downturns, which could impact procedure volumes. The most severe risk is a continued decline in investor confidence, which could drive the stock down to its 52-week low of $42.20, representing a potential 11.7% loss from current levels.
Over the next 12 months, the base case scenario, with a 50% probability, sees the stock trading in the range of $55-$65, aligning with the analyst average target of $62.69. The bull case, with a 30% probability, could see the stock reach $70-$94 if the company successfully executes on its TAVR strategy and clinical outcomes improve. The bear case, with a 20% probability, could see the stock fall to $42-$48 if clinical failures persist. The most likely scenario is a gradual recovery as the market digests the recent setbacks and the company continues to grow revenue at double-digit rates.
On a trailing basis, BSX trades at a PE of 48.65x, which is elevated and suggests the market had high expectations. However, the forward PE of 13.92x indicates that the market expects substantial earnings growth, making the stock appear undervalued on a forward basis. The PEG ratio of 0.88 further supports this view, as it suggests the stock is trading below its growth rate. Compared to peers in the medical devices industry, BSX's forward valuation is attractive, but the wide gap between trailing and forward multiples implies significant uncertainty. Overall, the stock appears undervalued if the company can deliver on its earnings growth projections, but overvalued if it fails to meet them.
Boston Scientific presents a compelling risk/reward opportunity for long-term investors. With an average analyst target of $62.69, implying a 31.2% upside from the current price of $47.80, and a forward PE of 13.92x, the stock appears undervalued relative to its growth prospects. However, the recent 55% decline highlights significant risks, including clinical failures and execution challenges. For investors with a high risk tolerance and a long-term horizon, BSX could be a good buy, but it is not suitable for those seeking stability or short-term gains. The key is to monitor clinical and operational developments closely.
BSX is better suited for long-term investment due to its growth-oriented business model and the potential for significant earnings growth over time. The stock's beta of 0.568 indicates lower volatility than the market, but the recent 55% decline shows that company-specific risks can cause sharp swings. Short-term trading is risky given the uncertainty around clinical outcomes and market sentiment. For long-term investors, a minimum holding period of 3-5 years is recommended to allow the company to execute on its pipeline and TAVR expansion, which should drive earnings growth and share price appreciation. The lack of a dividend makes it less attractive for income-focused investors, but its growth potential makes it a suitable holding for growth-oriented portfolios.